Skip to main content
Erschienen in: PharmacoEconomics 4/2009

01.04.2009 | Review Article

Reviewing the Cost Effectiveness of Rotavirus Vaccination

The Importance of Uncertainty in the Choice of Data Sources

verfasst von: Joke Bilcke, Philippe Beutels

Erschienen in: PharmacoEconomics | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Published health economic evaluations of rotavirus vaccination up until July 2008 were reviewed. We assess whether differences in the results and conclusions of the various studies are due to differences in methodological and modelling choices, and/or the way parameter uncertainty was taken into account, or whether these are merely the result of genuine country/region-specific differences.
No unambiguous single answer emerged as to whether universal rotavirus vaccination is or is not cost effective. The relevance and merits of each study need to be assessed within its context. This is illustrated by the fact that comparisons of different analyses for a single country show that one of the most important explanations for the variations in results and conclusions seems to be the use of different information sources for the estimation of input parameters.
Future studies should gather reliable and relevant information focusing on the most influential input parameters, i.e. rotavirus mortality (and efficacy against rotavirus deaths) for low- and middle-income countries, and a range of variables for high-income countries, including the incidence and cost of rotavirus hospitalization. Moreover, if no information is available for an important input parameter, the impact of a wide range of values should be explored rather than excluding it from the analysis or specifying a single-point value. Furthermore, future analyses may have to consider ways of accounting for herd immunity (e.g. by using a dynamic model).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9 (5): 565–72PubMedCrossRef Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9 (5): 565–72PubMedCrossRef
2.
Zurück zum Zitat Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344 (8): 564–72PubMedCrossRef Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344 (8): 564–72PubMedCrossRef
3.
Zurück zum Zitat Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74PubMedCrossRef Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74PubMedCrossRef
4.
Zurück zum Zitat Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434–46PubMedCrossRef Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 2006; 26 (5): 434–46PubMedCrossRef
5.
Zurück zum Zitat Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38PubMedCrossRef Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38PubMedCrossRef
6.
Zurück zum Zitat Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002–2006). Vaccine 2007; 25 (8): 1355–67PubMedCrossRef Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination: a review (2002–2006). Vaccine 2007; 25 (8): 1355–67PubMedCrossRef
7.
Zurück zum Zitat Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997 Drummond M, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press, 1997
8.
Zurück zum Zitat Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996 Gold M, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
9.
Zurück zum Zitat Beutels P, Scuffham P, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect D 2008; 8 (11): 727–33CrossRef Beutels P, Scuffham P, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach? Lancet Infect D 2008; 8 (11): 727–33CrossRef
10.
Zurück zum Zitat Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: 8–15; discussion 23–5PubMedCrossRef Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: 8–15; discussion 23–5PubMedCrossRef
11.
Zurück zum Zitat Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006 Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York: Oxford University Press, 2006
12.
Zurück zum Zitat Tebbens RJD, Thompson KM, Hunink MGM, et al. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Med Decis Making 2008; 28 (2): 182–200CrossRef Tebbens RJD, Thompson KM, Hunink MGM, et al. Uncertainty and sensitivity analyses of a dynamic economic evaluation model for vaccination programs. Med Decis Making 2008; 28 (2): 182–200CrossRef
13.
Zurück zum Zitat Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregivers’ burden and “no medical care” disease impact in Belgium. Med Decis Making. Epub 2008 Oct 23 Bilcke J, Van Damme P, Beutels P. Cost-effectiveness of rotavirus vaccination: exploring caregivers’ burden and “no medical care” disease impact in Belgium. Med Decis Making. Epub 2008 Oct 23
14.
Zurück zum Zitat Takala AK, Koskenniemi E, Joensuu J, et al. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Infect Dis 1998; 27 (2): 272–82PubMedCrossRef Takala AK, Koskenniemi E, Joensuu J, et al. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Infect Dis 1998; 27 (2): 272–82PubMedCrossRef
15.
Zurück zum Zitat Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenza type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000; 9 (1): 19–35PubMedCrossRef Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenza type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000; 9 (1): 19–35PubMedCrossRef
16.
Zurück zum Zitat Puliyel JM. Policy analysis of the use of hepatitis B, Haemophilus influenza type B, Streptococcus pneumoniae-conjugate and Rotavirus vaccines in the national immunization schedules [author reply]. Health Econ 2004; 13 (11): 1147–8PubMedCrossRef Puliyel JM. Policy analysis of the use of hepatitis B, Haemophilus influenza type B, Streptococcus pneumoniae-conjugate and Rotavirus vaccines in the national immunization schedules [author reply]. Health Econ 2004; 13 (11): 1147–8PubMedCrossRef
17.
Zurück zum Zitat Podewils LJ, Antil L, Hummelman E, et al. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192 Suppl. 1: S133–45CrossRef Podewils LJ, Antil L, Hummelman E, et al. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005; 192 Suppl. 1: S133–45CrossRef
18.
Zurück zum Zitat Carlin JB, Jackson T, Lane L, et al. Cost effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health 1999; 23 (6): 611–6PubMedCrossRef Carlin JB, Jackson T, Lane L, et al. Cost effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health 1999; 23 (6): 611–6PubMedCrossRef
19.
Zurück zum Zitat Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25 (52): 8851–60PubMedCrossRef Newall AT, Beutels P, Macartney K, et al. The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 2007; 25 (52): 8851–60PubMedCrossRef
20.
Zurück zum Zitat Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26 (5): 706–15PubMedCrossRef Melliez H, Levybruhl D, Boelle PY, et al. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008; 26 (5): 706–15PubMedCrossRef
21.
Zurück zum Zitat Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93 (1): 52–8PubMedCrossRef Ho AM, Nelson EA, Walker DG. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective. Arch Dis Child 2008; 93 (1): 52–8PubMedCrossRef
22.
Zurück zum Zitat Goossens LM, Standaert B, Hartwig N, et al. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26 (8): 1118–27PubMedCrossRef Goossens LM, Standaert B, Hartwig N, et al. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands. Vaccine 2008; 26 (8): 1118–27PubMedCrossRef
23.
Zurück zum Zitat Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales: part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25 (20): 3971–9PubMedCrossRef Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales: part II. The potential cost-effectiveness of vaccination. Vaccine 2007; 25 (20): 3971–9PubMedCrossRef
24.
Zurück zum Zitat Lorgelly PK, Joshi D, Iturriza Gómara M, et al. Exploring the cost-effectiveness of an immunisation programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2007; 136 (1): 44–55PubMed Lorgelly PK, Joshi D, Iturriza Gómara M, et al. Exploring the cost-effectiveness of an immunisation programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2007; 136 (1): 44–55PubMed
25.
Zurück zum Zitat Smith JC, Haddix AC, Teutsch SM, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995; 96 (4 Pt 1): 609–15PubMed Smith JC, Haddix AC, Teutsch SM, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. Pediatrics 1995; 96 (4 Pt 1): 609–15PubMed
26.
Zurück zum Zitat Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998; 279 (17): 1371–6PubMedCrossRef Tucker AW, Haddix AC, Bresee JS, et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. JAMA 1998; 279 (17): 1371–6PubMedCrossRef
27.
Zurück zum Zitat Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119 (4): 684–97PubMedCrossRef Widdowson MA, Meltzer MI, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007; 119 (4): 684–97PubMedCrossRef
28.
Zurück zum Zitat Rheingans RD, Constenla D, Antil L, et al. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21 (4): 205–16PubMedCrossRef Rheingans RD, Constenla D, Antil L, et al. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21 (4): 205–16PubMedCrossRef
29.
Zurück zum Zitat de Soárez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008; 23 (4): 221–30PubMedCrossRef de Soárez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica 2008; 23 (4): 221–30PubMedCrossRef
30.
Zurück zum Zitat Constenla D, O’Ryan M, Navarrete MS, et al. Potential cost effectiveness of a rotavirus vaccine in Chile. Rev Med Chil 2006; 134 (6): 679–88PubMed Constenla D, O’Ryan M, Navarrete MS, et al. Potential cost effectiveness of a rotavirus vaccine in Chile. Rev Med Chil 2006; 134 (6): 679–88PubMed
31.
Zurück zum Zitat Constenla D, Ortega-Barria E, Rheingans RD, et al. Economic impact of rotavirus vaccination in Panama. An Pediatr (Barc) 2008; 68 (2): 128–35CrossRef Constenla D, Ortega-Barria E, Rheingans RD, et al. Economic impact of rotavirus vaccination in Panama. An Pediatr (Barc) 2008; 68 (2): 128–35CrossRef
32.
Zurück zum Zitat Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25 (2): 373–80PubMedCrossRef Isakbaeva ET, Musabaev E, Antil L, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine 2007; 25 (2): 373–80PubMedCrossRef
33.
Zurück zum Zitat Constenla D, Perez-Schael I, Rheingans RD, et al. Assessment of the economic impact of the antiretroviral vaccine in Venezuela. Rev Panam Salud Publica 2006; 20 (4): 213–22PubMedCrossRef Constenla D, Perez-Schael I, Rheingans RD, et al. Assessment of the economic impact of the antiretroviral vaccine in Venezuela. Rev Panam Salud Publica 2006; 20 (4): 213–22PubMedCrossRef
34.
Zurück zum Zitat Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192 (10): 1720–6PubMedCrossRef Fischer TK, Anh DD, Antil L, et al. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam. J Infect Dis 2005; 192 (10): 1720–6PubMedCrossRef
35.
Zurück zum Zitat Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20 (1): 1–7PubMedCrossRef Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20 (1): 1–7PubMedCrossRef
36.
Zurück zum Zitat Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191–215PubMedCrossRef Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26 (3): 191–215PubMedCrossRef
37.
Zurück zum Zitat Vesikari T, Matson DO, Dennehy P, et al. Rotavirus Efficacy and Safety Trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354 (1): 23–33PubMedCrossRef Vesikari T, Matson DO, Dennehy P, et al. Rotavirus Efficacy and Safety Trial (REST) study team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354 (1): 23–33PubMedCrossRef
38.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity: United States, November 2007–May 2008. MMWR Morb Mortal Wkly Rep 2008; 57 (25): 697–700 Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity: United States, November 2007–May 2008. MMWR Morb Mortal Wkly Rep 2008; 57 (25): 697–700
39.
Zurück zum Zitat Rheingans RD, Constenla D, Antil L, et al. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21 (4): 192–204PubMedCrossRef Rheingans RD, Constenla D, Antil L, et al. Economic and health burden of rotavirus gastroenteritis for the 2003 birth cohort in eight Latin American and Caribbean countries. Rev Panam Salud Publica 2007; 21 (4): 192–204PubMedCrossRef
40.
Zurück zum Zitat Sartori AM, Valentim J, de Soárez PC, et al. Rotavirus morbidity and mortality in children in Brazil. Rev Panam Salud Publica 2008; 23 (2): 92–100PubMedCrossRef Sartori AM, Valentim J, de Soárez PC, et al. Rotavirus morbidity and mortality in children in Brazil. Rev Panam Salud Publica 2008; 23 (2): 92–100PubMedCrossRef
41.
Zurück zum Zitat Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 2004; 22 (25–26): 3312–22PubMedCrossRef Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 2004; 22 (25–26): 3312–22PubMedCrossRef
42.
Zurück zum Zitat Coyle D, Lee KM. Evidence-based economic evaluation: how the use of different data sources can impact results. In: Donaldson C, Mugford M, Vale L, editors. Evidence-based health economics: from effectiveness to efficiency in systematic review. London: BMJ Books, 2002: 55–66 Coyle D, Lee KM. Evidence-based economic evaluation: how the use of different data sources can impact results. In: Donaldson C, Mugford M, Vale L, editors. Evidence-based health economics: from effectiveness to efficiency in systematic review. London: BMJ Books, 2002: 55–66
43.
Zurück zum Zitat Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479–500PubMedCrossRef Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479–500PubMedCrossRef
44.
Zurück zum Zitat Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781–98PubMedCrossRef Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781–98PubMedCrossRef
45.
Zurück zum Zitat Manning WG, Fryback DG, Weinstein M. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 247–75 Manning WG, Fryback DG, Weinstein M. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 247–75
Metadaten
Titel
Reviewing the Cost Effectiveness of Rotavirus Vaccination
The Importance of Uncertainty in the Choice of Data Sources
verfasst von
Joke Bilcke
Philippe Beutels
Publikationsdatum
01.04.2009
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 4/2009
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200927040-00002

Weitere Artikel der Ausgabe 4/2009

PharmacoEconomics 4/2009 Zur Ausgabe